Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow EQ by emailGet an email when EQ pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about EQ, unsubscribe in one click. Privacy
📣 What EQ Says Is Next
fourth quarter of 2026 · “Advancing EQ504 toward the clinic, with the Phase 1 proof-of-mechanism study expected to initiate in the fourth quarter of 2026, and topline data anticipated approximately six months thereafter.”
Company press release, Aug 13, 2026 · SEC filing
fourth quarter of 2026 · “We expect to initiate this study in the fourth quarter of 2026 and report topline data approximately six months thereafter.”
Company press release, Aug 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full EQ picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for EQ and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.